FDA Advisory Committee rejects serelaxin for Acute Heart Failure - Novartis

The FDA Cardiovascular and Renal Drugs Advisory Committee will not recommend serelaxin (proposed name Reasanz) from Novartis for treatment of Acute Heart Failure on the basis of a single trial. There is insufficient evidence to support the claims improving symptoms through reduction of the rate of worsening heart failure.